Merck & Co vs Novartis
Merck & Co (MRK), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Merck & Co is worth $354.4B on the stock market and Novartis $301.5B: Merck & Co is valued at 18% more. Merck & Co trades at 145 times earnings and Novartis at 30.5. Over the past year Merck & Co's share price has moved +49.8% and Novartis's +25.1%.
Key facts
- Merck & Co market value
- $354.4B
- Novartis market value
- $301.5B
- Merck & Co P/E
- 145
- Novartis P/E
- 30.5
- Merck & Co revenue
- $65BFY to 2025-12-31
- Novartis revenue
- $54.5BFY to 2025-12-31
- Superinvestors holding both
- 8
Market values as of .
| Measure | Merck & Co | Novartis |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $354.4Bhigher | $301.5Blower |
| Revenue | $65Bhigher | $54.5Blower |
| Earnings | $18.3Bhigher | $14Blower |
| Employees | 73,000lower | 75,267higher |
| Total assets | $136.9Bhigher | $110.9Blower |
| Valuation | ||
| P/E | 145higher | 30.5lower |
| P/S | 5.5lower | 5.5higher |
| P/B | 7.9 | — |
| Dividend yield | 2.33% | — |
| Profitability | ||
| Operating margin | — | 32.4% |
| Balance sheet | ||
| Net assets | $52.6Bhigher | $46.1Blower |
| Total liabilities | $84.2Bhigher | $64.4Blower |
| Total debt | $49.3Bhigher | $28.7Blower |
| Cash on hand | $14.6Bhigher | $11.4Blower |
| Price change | ||
| Today | -0.48%lower | -0.35%higher |
| 1 year | +49.8%higher | +25.1%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (8)
- Thomas Kahn4.9% / 0.3%
- Ken Fisher1.7% / 0.7%
- Jeremy Grantham (co-founder)1.6% / 0.1%
- Charles Brandes (founder)1.5% / 0.2%
- Brandon Haley0.2% / 0.4%
- Murray Stahl0.1% / <0.1%
- Dodge & Cox team<0.1% / 0.1%
- Rajiv Jain<0.1% / <0.1%
Merck & Co only (15)
- Bill Smead7.1%
- Bill Nygren2.1%
- Howard Gleicher2.0%
- Josef Lakonishok1.4%
- Prem Watsa0.9%
- Christopher Bloomstran0.6%
- Sarah Ketterer0.6%
- Mark Boyar0.5%
- Cliff Asness0.4%
- Temasek0.3%
- David Shaw (founder)0.2%
- Joel Greenblatt0.2%
- Ken Griffin0.1%
- Mairs & Power team0.1%
- Thomas Russo<0.1%
Novartis only (5)
- Tweedy, Browne team0.8%
- Primecap team0.6%
- Larry Robbins0.3%
- Andrew Spokes0.2%
- Lee Ainslie<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Merck & Co / Novartis). Who owns MRK · Who owns NVS
More on Merck & Co
Further comparisons
Merck & Co against its closest peers
Novartis against its closest peers
Learn
Questions and answers
Which is bigger, Merck & Co or Novartis?
By market value, Merck & Co is the larger: $354.4B against $301.5B for Novartis. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $54.5B for Novartis.
Which has the higher P/E ratio?
Merck & Co: 145, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Merck & Co: $49.3B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Merck & Co and Novartis?
In their latest 13F filings, Thomas Kahn, Ken Fisher, Jeremy Grantham (co-founder), Charles Brandes (founder), Brandon Haley, Murray Stahl, Dodge & Cox team and Rajiv Jain hold both.
Cite this page
Funkfolio, “Merck & Co vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/mrk-vs-nvs
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.